Edwards Lifesciences (EW) Receivables (2009 - 2026)

Edwards Lifesciences' Receivables history runs 18 years deep, the most recent figure standing at $973.0 million for Q1 2026.

• In Q1 2026, Receivables rose 29.41% year-over-year to $973.0 million; the TTM figure through Mar 2026 stood at $973.0 million (up 29.41% YoY), while the FY2025 annual figure was $912.1 million, up 520.05% from the prior year.
• Receivables was $973.0 million for Q1 2026 at Edwards Lifesciences, up from $912.1 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $973.0 million in Q1 2026 to a low of $147.1 million in Q4 2024.
• Historically, Receivables has averaged $767.9 million across 5 years, with a median of $811.5 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Receivables tumbled 82.24% in 2024, then soared 520.05% in 2025.
• A 5-year view of Receivables shows it stood at $699.1 million in 2022, then advanced by 18.45% to $828.1 million in 2023, then sank by 82.24% to $147.1 million in 2024, then jumped by 520.05% to $912.1 million in 2025, then increased by 6.68% to $973.0 million in 2026.
• The last three Receivables figures came in at $973.0 million (Q1 2026), $912.1 million (Q4 2025), and $892.8 million (Q3 2025), per Business Quant data.